Otsuka Medical Devices (Otsuka), a subsidiary of Otsuka Holdings Co., Ltd., and Veryan Medical (Veryan) recently announced the completion of the acquisition of Veryan by Otsuka through its UK subsidiary Otsuka Medical devices UK. Ltd.
Veryan’s BioMimics 3D peripheral vascular stent received approval from the US Food and Drug Administration (FDA) in October 2018. Following the acquisition, Veryan and Otsuka Medical Devices plan to collaborate in developing Swirling Flow stents for use in the treatment of vascular disease. As part of the acquisition, Veryan’s operations in Galway, Ireland will be retained by Otsuka Medical Devices, and will play a key role in the continued development of the Swirling Flow technology.
Otsuka Pharmaceutical is a global health care company with the corporate philosophy: “Otsuka – people creating new products for better health worldwide.” Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products for the treatment of diseases, and nutraceutical products for the maintenance of everyday health.
This was reported by Otsuka on December 13, 2018.
Contact Information: Otsuka America Pharmaceutical, Inc. 2440 Research Boulevard, Rockville, Maryland 20850; (301) 424-9055; Website: www.otsuka-us.com
Contact Information: Veryan Medical Ltd., 15 City Business Centre, Brighton Road, Horsham, West Sussex RH13 5BB, UK; +44 (0)1403 258984; Website: www.veryanmed.com